Phase 1 Muscle Invasive Bladder Cancer Clinical Trials
15 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423
Recruiting
Phase 1Phase 2
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Non Muscle Invasive Bladder Cancer
SURGE Therapeutics75 enrolled20 locationsNCT05710848
Recruiting
Phase 1
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Non Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center55 enrolled7 locationsNCT05126472
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting
Phase 1
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Non Muscle Invasive Bladder Cancer
Pfizer294 enrolled47 locationsNCT07206225
Recruiting
Phase 1
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Urothelial Carcinoma BladderNon Muscle Invasive Bladder CancerNMIBC+3 more
Aura Biosciences55 enrolled17 locationsNCT05483868
Recruiting
Phase 1Phase 2
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Pancreatic Ductal Adenocarcinoma (PDAC)Triple Negative Breast Cancer(TNBC)Colorectal Cancer (CRC)+6 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting
Phase 1Phase 2
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734
Recruiting
Phase 1
A Phase I Intravesical PPM Therapy for NMIBC
Non Muscle Invasive Bladder Cancer
VA Office of Research and Development29 enrolled1 locationNCT05519241
Recruiting
Phase 1
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
Muscle Invasive Bladder Cancer
First Affiliated Hospital of Chongqing Medical University10 enrolled1 locationNCT06916494
Recruiting
Phase 1
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.170 enrolled1 locationNCT06108492
Recruiting
Phase 1
A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
The Affiliated Hospital of Xuzhou Medical University16 enrolled1 locationNCT06632964
Recruiting
Phase 1Phase 2
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer
Non Muscle Invasive Bladder Cancer
Binhui Biopharmaceutical Co., Ltd.30 enrolled1 locationNCT05232136
Recruiting
Phase 1Phase 2
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd.24 enrolled6 locationsNCT06378242
Completed
Phase 1
SUBurothelial DUrvalumab injEction-1 (SUBDUE-1)
Muscle invasive or high risk non muscle invasive bladder cancer
South Metropolitan Health Service12 enrolled1 locationACTRN12620000063910